NVO has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
This is the expense the company spent on research and development. Novo Nordisk A/S's research and development for the three months ended in Dec. 2016 was $634 Mil. Its research and development for the trailing twelve months (TTM) ended in Dec. 2016 was $2,151 Mil.
This is the expense the company spent on research and development.
Novo Nordisk A/S Research & Development for the trailing twelve months (TTM) ended in Dec. 2016 was 493.237392888 (Mar. 2016 ) + 503.096209032 (Jun. 2016 ) + 520.861575538 (Sep. 2016 ) + 633.826782372 (Dec. 2016 ) = $2,151 Mil.
* All numbers are in millions except for per share data and ratio. All numbers are in their local exchange's currency.
If competitive advantage is created by a patent or tech advantage, at some point it will disappear.
High R&D usually dictates high SG&A which threatens the competitive advantage.
Novo Nordisk A/S Annual Data
|Research & Development||1,669||1,425||1,540||1,704||1,703||1,916||2,156||2,280||1,986||2,065|
Novo Nordisk A/S Quarterly Data
|Research & Development||633||640||471||457||495||589||493||503||521||634|